瑞舒伐他汀强化治疗对于ACS患者LDL-C及C反应蛋白的影响

The impact of enhanced rosuvastatin treatment on the levels of LDL- C and hs- CRP in ACS patients

目的观察急性冠脉综合征(acute coronary syndrome ACS)患者经过瑞舒伐他汀强化治疗后血清超敏C反应蛋白(hs-CRP)及血脂水平(LDL-C)变化。方法 68例ACS患者,随机分为瑞舒伐他汀强化治疗组(简称强化组34例)和常规治疗组(34例),强化治疗组在标准治疗基础上每日口服瑞舒伐他汀20 mg,常规治疗组患者在标准治疗基础上每日口服瑞舒伐他汀10 mg,比较两组患者1周,2周,4周LDL-C和hs-CRP水平,并观察4周后患者血清转氨酶及CK变化。结果 (1)强化组LDL-C水平1周明显低于常规治疗组(P<0.05),强化组hs-CRP水平4周明显低于常规治疗组(P<0.05),(2)强化组LDL-C及hs-CRP水平1周,2周,4周均明显低于治疗前(P<0.05),常规组:治疗后1周LDL-C水平较治疗前无显著差异(P>0.05),2周,4周后较治疗前可见显著差异(P<0.05),hs-CRP水平治疗后1周2周4周较治疗前存在显著性差异(P<0.05);且无肝功能损害及横纹肌溶解表现。结论强化瑞舒伐他汀短期治疗后可迅速明显降低患者血脂(LDL-C)及hs-CRP水平。

Objective To detect the effects of intensive rosuvastatin therapy on hypersensitive C-reactive protein（ hs- CRP） and low density lipoprotein cholesterol（ LDL- C） in patients with acute coronary syndrome（ ACS）. Methods 68 cases of ACS patients were randomized into intensive rosuvastatin therapy group（ intensive group,n = 34） and general rosuvastatin therapy group（ general group,n = 34）. Based on standard treatment,patients in intensive group were given rosuvastatin 20 mg / d oral and in general group were given rosuvastatin 10 mg / d oral. The serum levels of hs- CRP and LDL- C of the two groups were compared and analyzed before and 1,2,4weeks after treatment respectively. In addition,we observed the changes of serum aminotransferase and CK 4 weeks after the treatment. Results One week after the strengthen treatment,serum LDL- C levels in intensive group reduced rapidly and lower than that in general group（ P〈0. 05）. And four weeks later,hs- CRP level in intensive group was less than that in general rosuvastatin group（ P〈0. 05）. In intensive group,serum LDL- C and hs- CRP levels reduced after the strengthen treatment（ P〈0. 05）. In general rosuvastatin therapy group,1 week after rosuvastatin treatment serum LDL- C level had no significant difference compared with the serum LDL- C level before the treatment（ P〉0. 05）. 2,4 weeks after rosuvastatin treatment serum LDL- C levels significantly reduced（ P〈0. 05）,however,after the treatment the serum hs-CRP levels have significant differences compared with the serum hs- CRP levels before the treatment（ P〈0.05）. And had no liver function damage and rhabdomyolysis performance. Conclusions The LDL- C and hs-CRP levels can rapidly reduce after the treatment.